Boccia L, Gamakharia S, Coester B, Whiting L, Lutz TA, Le Foll C
The Trump administrations recent Most Favored Nation (MFN) pricing deal, announced in November 2025, represented the first major effort to close that gap, anchoring widely discussed consumer prices around $350 per month for many injectable GLP-1 through manufacturer self-pay programs
The trials also looked at safety and side effects
Spending on platforms that support mental health such as Headway, BetterHelp and therapy-focused apps such as Ivy also increased in 2025
Update on Once-Monthly Weight Loss Drug Maritide Following Phase II Clinical Trial The Phase II trial of the once-monthly weight loss drug Maridebart cafraglutide (Amgen), also known as MariTide or AMG133, shows high discontinuation rates, largely due to gastrointestinal side effects
Foundayo (orforglipron): the pill with no food or water rules Foundayo is the brand name Eli Lilly uses for orforglipron, the first non-peptide oral GLP-1 receptor agonist
